Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

PHASE2CompletedINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

February 20, 2018

Primary Completion Date

July 25, 2019

Study Completion Date

July 25, 2019

Conditions
Avian InfluenzaInfluenzaInfluenza Immunisation
Interventions
DRUG

AS03

AS03 oil-in-water emulsion adjuvant.

BIOLOGICAL

Inactivated influenza H7N9 vaccine

Monovalent 2017 H7N9 inactivated influenza vaccine

BIOLOGICAL

Influenza Virus Quadrivalent Inactivated Vaccine

A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N2) and 2 influenza B subtypes (B Yamata lineage and B Victoria lineage).

OTHER

Phosphate Buffered Saline (PBS) diluent

Diluent for Adjuvanted 2017 Monovalent Inactivated Influenza A/H7N9 vaccine (2017 H7N9IIV)

Trial Locations (4)

35294-2050

University of Alabama at Birmingham School of Medicine - Alabama Vaccine Research Clinic, Birmingham

21201-1509

University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore

45229-3039

Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati

37232-0011

Vanderbilt University Medical Center - Infectious Diseases, Nashville

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03318315 - Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 | Biotech Hunter | Biotech Hunter